Itamar Medical Inc. Release: Study Shows that Flavonoid Supplements Prevent Impairment of Endothelial Function After High-Fat Meals

February 18, 2009- Itamar Medical, an international medical technology company developing noninvasive diagnostic technology using the Peripheral Arterial Tone (PAT™) Signal, announced today the use of the company's patented Endo-PAT2000 in the Carolinas HealthCare System's study of the potential benefits of flavonoid supplementation on endothelial function. The Endo-PAT2000 was used to measure participants' endothelial function in a study designed to evaluate how flavonoid supplementation can prevent the adverse impact on endothelial function caused by a high-fat meal. Various foods high in flavonoids such as black tea, dark chocolate, red wine and citrus fruits have been associated with lower risk for cardiovascular disease, and medical research conducted with foods high in flavonoids have demonstrated improvement in endothelial dysfunction, the earliest clinically detectable stage of cardiovascular disease.

Itamar Medical's Endo-PAT2000 was used to measure endothelial function in 23 healthy volunteers before and after 4 weeks of flavonoid and placebo supplementation. According to Endo-PAT measurements, eating a high-fat meal produced an acute decline in endothelial function for all volunteers before supplementation, and after 4 weeks of placebo supplementation. However, Endo-PAT measurements indicated no similar acute decline in endothelial function from the consumption of a high-fat meal after 4 weeks of flavonoid supplementation. Study results indicate that flavonoid supplementation can reduce the acute impairment of endothelial function caused by a high-fat meal, adding to the growing medical literature on the long-term benefits of flavonoid supplementation on endothelial dysfunction and cardiac health.

"We are honored that the Carolinas HealthCare System chose to use the Endo-PAT2000 for research that called for a reliable measurement of endothelial dysfunction," stated Itamar Medical President and CEO Dov Rubin. "The Endo-PAT2000 is the only medical device that is FDA-cleared as an aid in the detection of endothelial dysfunction. We regard the use of Endo-PAT2000 by researching institutions such as the Carolinas HealthCare System and others as an endorsement of the Endo-PAT's effectiveness and value in the diagnosis of endothelial dysfunction." Itamar Medical has developed the first simple, inexpensive, office-based diagnostic test for endothelial dysfunction. The Endo-PAT2000 is a noninvasive device for the diagnosis of endothelial dysfunction using bio-sensors mounted on the patients' fingers that measure minute changes in vascular tone using Itamar Medical's PAT Signal technology. The Endo-PAT2000 adds an unparalleled dimension to the prevention of cardiovascular disease by enabling physicians to accurately assess endothelial dysfunction and modify patient management accordingly. Itamar Medical (TASE: ITMR) is a medical technology company developing noninvasive diagnostic systems using Peripheral Arterial Tone (PAT™) signal, including the Watch-PAT™ systems for the diagnosis of sleep related breathing disorders and the Endo-PAT™ systems for assessment of endothelial function, a condition recognized as an early stage of cardiovascular and cerebrovascular diseases.

For further information see http://www.itamar-medical.com